^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | bortezomib (Proteasome inhibitor) + pegylated liposomal doxorubicin (Topoisomerase II inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Caelyx pegylated liposomal is indicated:...in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant...
Secondary therapy:
doxorubicin hydrochloride
